Symbols / LIPO
LIPO Chart
About
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 785.54K |
| Enterprise Value | -806.14K | Income | -5.33M | Sales | 389.78K |
| Book/sh | 0.32 | Cash/sh | 0.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | 5 | IPO | — |
| P/E | — | Forward P/E | -0.05 | PEG | — |
| P/S | 2.02 | P/B | 0.53 | P/C | — |
| EV/EBITDA | 0.15 | EV/Sales | -2.07 | Quick Ratio | 2.89 |
| Current Ratio | 3.24 | Debt/Eq | 17.75 | LT Debt/Eq | — |
| EPS (ttm) | -2.26 | EPS next Y | -3.20 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-03-28 06:00 | ROA | -149.95% |
| ROE | -3.62% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -13.88% | Profit Margin | 0.00% | Shs Outstand | 4.62M |
| Shs Float | 4.33M | Short Float | 2.35% | Short Ratio | 3.32 |
| Short Interest | — | 52W High | 3.48 | 52W Low | 0.15 |
| Beta | 0.09 | Avg Volume | 7.33K | Volume | 570.00 |
| Target Price | — | Recom | None | Prev Close | $0.17 |
| Price | $0.17 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.17
Latest analyst target
3. DCF / Fair value
$-11.01
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.17
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-04-09 | init | Maxim Group | — → Buy | $2 |
- Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market - GlobeNewswire Fri, 20 Jun 2025 07
- Nasdaq to delist certain securities suspended from trading (NDAQ:NASDAQ) - Seeking Alpha Wed, 24 Sep 2025 07
- Novel Lipo-MIT–Based Triplet Drives Responses in R/R Myeloma - OncLive Fri, 15 Aug 2025 07
- What makes LIPO stock attractive to growth funds - Weekly Trend Report & Technical Pattern Recognition Alerts - mfd.ru hu, 12 Feb 2026 19
- Edison ready to return to the stock market: Edf is considering an IPO and eyeing the Milan Stock Exchange - firstonline.info ue, 13 Jan 2026 08
- LIPO - Lipella Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan Mon, 09 Jan 2023 13
- Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results - Benzinga Mon, 23 Jun 2025 07
- Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis $LIPO - MarketBeat Wed, 21 Dec 2022 01
- Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PR Newswire ue, 16 Dec 2025 08
- What is the dividend yield of LIPO - Weekly Market Report & Stepwise Swing Trade Plans - mfd.ru hu, 12 Feb 2026 22
- Hanwha Life finalizes acquisition of Nobu Bank in Indonesia this month - CHOSUNBIZ - Chosunbiz Wed, 02 Apr 2025 07
- Xiaomi 17 Pro Max out of stock as fans swarm stores: Hi-tech, but cheaper, than iPhone 17 Pro Max? - Gulf News Mon, 29 Sep 2025 07
- Lululemon Founder Chip Wilson Sells Millions of Dollars of Stock - Barron's Sat, 21 Sep 2019 07
- Taking Vitamins? Here’s Why They Might Not Be Doing Their Job (Yet) - The Everygirl Wed, 12 Nov 2025 08
- Kailyn Lowry Says 'Rest in Peace to My Double Chin' as She Shares Results of Latest Cosmetic Procedure - People.com Mon, 25 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10000 | 7590 | — | Purchase at price 0.76 per share. | KAUFMAN JONATHAN H | Chief Executive Officer | — | 2024-05-14 00:00:00 | D |
| 1 | 55000 | 45452 | — | Purchase at price 0.79 - 0.87 per share. | KAUFMAN JONATHAN H | Chief Executive Officer | — | 2024-03-19 00:00:00 | D |
| 2 | 144906 | 100000 | — | Stock Award(Grant) at price 0.69 per share. | CHANCELLOR MICHAEL B. | Officer, Director and Beneficial Owner | — | 2024-03-13 00:00:00 | D |
| 3 | 144906 | 100000 | — | Stock Award(Grant) at price 0.69 per share. | KAUFMAN JONATHAN H | Chief Executive Officer | — | 2024-03-13 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -5.01M | -4.61M | -2.59M | -1.86M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -5.02M | -4.62M | -2.60M | -1.87M |
| ReconciledDepreciation | 2.89K | 1.69K | 0.00 | |
| ReconciledCostOfRevenue | 3.61M | 3.04M | 2.55M | 1.46M |
| EBITDA | -5.01M | -4.61M | -2.59M | -1.86M |
| EBIT | -5.02M | -4.61M | -2.59M | -1.86M |
| NetInterestIncome | 64.28K | 126.99K | -7.93K | -6.73K |
| InterestExpense | 0.00 | 10.85K | 9.61K | 6.83K |
| InterestIncome | 64.28K | 137.84K | 1.68K | 104.00 |
| NormalizedIncome | -5.02M | -4.62M | -2.60M | -1.87M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -5.02M | -4.62M | -2.60M | -1.87M |
| TotalExpenses | 5.62M | 5.20M | 2.77M | 2.18M |
| TotalOperatingIncomeAsReported | -5.08M | -4.75M | -2.59M | -1.92M |
| DilutedAverageShares | 1.05M | 750.38K | 507.58K | 717.99K |
| BasicAverageShares | 1.05M | 750.38K | 507.58K | 717.99K |
| DilutedEPS | -4.79 | -6.16 | -5.12 | -2.60 |
| BasicEPS | -4.79 | -6.16 | -5.12 | -2.60 |
| DilutedNIAvailtoComStockholders | -5.02M | -4.62M | -2.60M | -1.87M |
| NetIncomeCommonStockholders | -5.02M | -4.62M | -2.60M | -1.87M |
| NetIncome | -5.02M | -4.62M | -2.60M | -1.87M |
| NetIncomeIncludingNoncontrollingInterests | -5.02M | -4.62M | -2.60M | -1.87M |
| NetIncomeContinuousOperations | -5.02M | -4.62M | -2.60M | -1.87M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -5.02M | -4.62M | -2.60M | -1.87M |
| OtherIncomeExpense | -45.00 | 57.09K | ||
| OtherNonOperatingIncomeExpenses | -45.00 | 57.09K | ||
| NetNonOperatingInterestIncomeExpense | 64.28K | 126.99K | -7.93K | -6.73K |
| InterestExpenseNonOperating | 0.00 | 10.85K | 9.61K | 6.83K |
| InterestIncomeNonOperating | 64.28K | 137.84K | 1.68K | 104.00 |
| OperatingIncome | -5.08M | -4.75M | -2.59M | -1.92M |
| OperatingExpense | 2.00M | 2.16M | 226.19K | 718.38K |
| ResearchAndDevelopment | 2.55M | 1.46M | ||
| SellingGeneralAndAdministration | 2.00M | 2.16M | 226.19K | 718.38K |
| GeneralAndAdministrativeExpense | 2.00M | 2.16M | 226.19K | 718.38K |
| OtherGandA | 2.00M | 2.16M | 226.19K | 718.38K |
| GrossProfit | -3.08M | -2.59M | -2.36M | -1.20M |
| CostOfRevenue | 3.61M | 3.04M | 2.55M | 1.46M |
| TotalRevenue | 536.36K | 449.62K | 184.16K | 259.35K |
| OperatingRevenue | 536.36K | 449.62K | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 1.21M | 756.74K | 717.99K | 717.99K |
| ShareIssued | 1.21M | 756.74K | 717.99K | 717.99K |
| TotalDebt | 47.60K | 136.59K | 429.52K | 282.96K |
| TangibleBookValue | 1.92M | 3.14M | 4.68M | 1.42M |
| InvestedCapital | 1.92M | 3.14M | 4.95M | 1.50M |
| WorkingCapital | 1.86M | 3.04M | 4.62M | 1.47M |
| NetTangibleAssets | 1.92M | 3.14M | 4.68M | 1.42M |
| CapitalLeaseObligations | 47.60K | 136.59K | 154.52K | 207.96K |
| CommonStockEquity | 1.92M | 3.14M | 4.68M | 1.42M |
| PreferredStockEquity | 33.00 | 159.00 | ||
| TotalCapitalization | 1.92M | 3.14M | 4.68M | 1.47M |
| TotalEquityGrossMinorityInterest | 1.92M | 3.14M | 4.68M | 1.42M |
| StockholdersEquity | 1.92M | 3.14M | 4.68M | 1.42M |
| RetainedEarnings | -15.34M | -10.32M | -5.70M | -3.11M |
| AdditionalPaidInCapital | 17.26M | 13.47M | 10.38M | 4.53M |
| CapitalStock | 154.00 | 75.00 | 574.00 | 546.00 |
| CommonStock | 121.00 | 75.00 | 574.00 | 387.00 |
| PreferredStock | 33.00 | 0.00 | 0.00 | 159.00 |
| TotalLiabilitiesNetMinorityInterest | 754.42K | 432.73K | 1.27M | 589.34K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 47.37K | 96.26K | 248.71K |
| TradeandOtherPayablesNonCurrent | 0.00 | 30.35K | ||
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 47.37K | 96.26K | 218.36K |
| LongTermCapitalLeaseObligation | 0.00 | 47.37K | 96.26K | 168.36K |
| LongTermDebt | 50.00K | |||
| CurrentLiabilities | 754.42K | 385.36K | 1.18M | 340.62K |
| OtherCurrentLiabilities | 67.83K | 50.16K | ||
| CurrentDebtAndCapitalLeaseObligation | 47.60K | 89.22K | 333.26K | 64.60K |
| CurrentCapitalLeaseObligation | 47.60K | 89.22K | 58.26K | 39.60K |
| CurrentDebt | 275.00K | 25.00K | ||
| OtherCurrentBorrowings | 275.00K | 25.00K | ||
| LineOfCredit | 0.00 | |||
| PayablesAndAccruedExpenses | 706.81K | 296.13K | 844.99K | 276.03K |
| CurrentAccruedExpenses | 318.62K | 106.07K | 460.64K | 229.13K |
| InterestPayable | 0.00 | 3.60K | 27.45K | |
| Payables | 388.19K | 190.07K | 384.36K | 46.90K |
| TotalTaxPayable | 52.05K | |||
| AccountsPayable | 388.19K | 138.02K | 384.36K | 46.90K |
| TotalAssets | 2.67M | 3.58M | 5.95M | 2.01M |
| TotalNonCurrentAssets | 56.62K | 147.89K | 150.82K | 204.80K |
| NetPPE | 56.62K | 147.89K | 150.82K | 204.80K |
| AccumulatedDepreciation | -130.43K | -127.54K | -125.86K | |
| GrossPPE | 187.05K | 275.44K | 276.68K | 204.80K |
| OtherProperties | 46.75K | 135.14K | 150.82K | 204.80K |
| MachineryFurnitureEquipment | 140.29K | 140.29K | 125.86K | |
| CurrentAssets | 2.62M | 3.43M | 5.80M | 1.81M |
| PrepaidAssets | 347.68K | 103.26K | 563.89K | 93.72K |
| Receivables | 84.71K | 32.29K | 113.66K | 0.00 |
| OtherReceivables | 84.71K | 32.29K | 113.66K | |
| CashCashEquivalentsAndShortTermInvestments | 2.18M | 3.29M | 5.12M | 1.71M |
| OtherShortTermInvestments | 0.00 | 300.55K | ||
| CashAndCashEquivalents | 2.18M | 3.29M | 5.12M | 1.41M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -3.95M | -3.16M | -1.83M | -989.27K |
| RepaymentOfDebt | 0.00 | -275.00K | 0.00 | |
| IssuanceOfDebt | 0.00 | 275.00K | 0.00 | |
| IssuanceOfCapitalStock | 2.84M | 1.61M | 4.96M | 2.10M |
| CapitalExpenditure | -14.43K | |||
| InterestPaidSupplementalData | 11.91K | 11.36K | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 2.18M | 3.29M | 5.12M | 1.41M |
| BeginningCashPosition | 3.29M | 5.12M | 1.41M | 606.74K |
| ChangesInCash | -1.11M | -1.83M | 3.71M | 807.09K |
| FinancingCashFlow | 2.84M | 1.34M | 5.24M | 2.10M |
| CashFlowFromContinuingFinancingActivities | 2.84M | 1.34M | 5.24M | 2.10M |
| ProceedsFromStockOptionExercised | 1.61M | 0.00 | ||
| NetPreferredStockIssuance | 2.84M | 1.61M | ||
| PreferredStockIssuance | 2.84M | 1.61M | ||
| NetCommonStockIssuance | 0.00 | 4.96M | 2.10M | |
| CommonStockIssuance | 0.00 | 4.96M | 2.10M | |
| NetIssuancePaymentsOfDebt | 0.00 | -275.00K | 275.00K | 0.00 |
| NetShortTermDebtIssuance | 0.00 | -275.00K | 0.00 | 0.00 |
| ShortTermDebtPayments | 0.00 | -275.00K | 0.00 | |
| ShortTermDebtIssuance | 0.00 | |||
| NetLongTermDebtIssuance | -250.00K | 275.00K | 0.00 | |
| LongTermDebtPayments | -250.00K | 0.00 | ||
| LongTermDebtIssuance | 0.00 | 275.00K | 0.00 | |
| InvestingCashFlow | 0.00 | -14.43K | 300.55K | -300.55K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -14.43K | 300.55K | -300.55K |
| NetInvestmentPurchaseAndSale | 0.00 | 300.55K | -300.55K | |
| SaleOfInvestment | 0.00 | 300.55K | ||
| PurchaseOfInvestment | -300.55K | |||
| NetPPEPurchaseAndSale | 0.00 | -14.43K | 0.00 | |
| PurchaseOfPPE | 0.00 | -14.43K | 0.00 | |
| OperatingCashFlow | -3.95M | -3.15M | -1.83M | -989.27K |
| CashFlowFromContinuingOperatingActivities | -3.95M | -3.15M | -1.83M | -989.27K |
| ChangeInWorkingCapital | 113.23K | -9.11K | 9.52K | 197.61K |
| ChangeInOtherWorkingCapital | -52.43K | 81.37K | -113.66K | 69.03K |
| ChangeInOtherCurrentLiabilities | 17.67K | 22.87K | ||
| ChangeInOtherCurrentAssets | -599.00 | -2.25K | 538.00 | 1.88K |
| ChangeInPayablesAndAccruedExpense | 410.68K | -548.86K | 592.82K | 196.75K |
| ChangeInAccruedExpense | 160.51K | -302.52K | 255.36K | 174.39K |
| ChangeInPayable | 250.18K | -246.34K | 337.46K | 22.36K |
| ChangeInAccountPayable | 250.18K | -246.34K | 337.46K | 22.36K |
| ChangeInPrepaidAssets | -244.42K | 460.63K | -470.18K | -70.06K |
| ChangeInReceivables | -113.66K | 69.03K | ||
| OtherNonCashItems | 200.00K | 121.20K | 9.61K | 6.83K |
| StockBasedCompensation | 749.40K | 1.36M | 747.40K | 728.80K |
| DepreciationAmortizationDepletion | 2.89K | 1.69K | 0.00 | |
| DepreciationAndAmortization | 2.89K | 1.69K | 0.00 | |
| Depreciation | 2.89K | 1.69K | ||
| OperatingGainsLosses | 747.40K | -57.04K | ||
| GainLossOnInvestmentSecurities | 747.40K | 728.80K | ||
| NetIncomeFromContinuingOperations | -5.02M | -4.62M | -2.60M | -1.87M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LIPO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|